Cover Image
市場調查報告書

Bionor Pharma ASA:產品平台分析

Bionor Pharma ASA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251649
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
Bionor Pharma ASA:產品平台分析 Bionor Pharma ASA - Product Pipeline Review - 2015
出版日期: 2015年07月29日 內容資訊: 英文 37 Pages
簡介

Trellis Bioscience, Inc.是發現、開發針對感染疾病和癌症症狀的新劃時代治療用抗體之生物科技企業。

本報告提供Bionor Pharma ASA的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Bionor Pharma ASA的基本資料

  • Bionor Pharma ASA概要
  • 主要資訊
  • 企業資料

Bionor Pharma ASA:R&D概要

  • 主要的治療範圍

Bionor Pharma ASA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Bionor Pharma ASA:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Bionor Pharma ASA:藥物簡介

  • Vacc-4x
  • Vacc-C5
  • Vacc-4x + Vacc-C5
  • Vacc-Flu
  • Vacc-HCV
  • Vacc-CMV
  • Vacc-HPV

Bionor Pharma ASA:開發平台分析

  • 各給藥途徑
  • 各分子類型

Bionor Pharma ASA:最近的開發平台趨勢

Bionor Pharma ASA:企業發表

Bionor Pharma ASA:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07207CDB

Summary

Global Markets Direct's, 'Bionor Pharma ASA - Product Pipeline Review - 2015', provides an overview of the Bionor Pharma ASA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bionor Pharma ASA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Bionor Pharma ASA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Bionor Pharma ASA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Bionor Pharma ASA's pipeline products

Reasons to buy

  • Evaluate Bionor Pharma ASA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Bionor Pharma ASA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Bionor Pharma ASA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Bionor Pharma ASA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bionor Pharma ASA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Bionor Pharma ASA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Bionor Pharma ASA Snapshot
    • Bionor Pharma ASA Overview
    • Key Information
    • Key Facts
  • Bionor Pharma ASA - Research and Development Overview
    • Key Therapeutic Areas
  • Bionor Pharma ASA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Bionor Pharma ASA - Pipeline Products Glance
    • Bionor Pharma ASA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Bionor Pharma ASA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Bionor Pharma ASA - Drug Profiles
    • Vacc-4x
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vacc-C5
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vacc-4x + Vacc-C5
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vacc-Flu
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vacc-HCV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vacc-CMV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vacc-HPV
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Bionor Pharma ASA - Pipeline Analysis
    • Bionor Pharma ASA - Pipeline Products by Route of Administration
    • Bionor Pharma ASA - Pipeline Products by Molecule Type
  • Bionor Pharma ASA - Recent Pipeline Updates
  • Bionor Pharma ASA - Company Statement
  • Bionor Pharma ASA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Bionor Pharma ASA, Key Information
  • Bionor Pharma ASA, Key Facts
  • Bionor Pharma ASA - Pipeline by Indication, 2015
  • Bionor Pharma ASA - Pipeline by Stage of Development, 2015
  • Bionor Pharma ASA - Monotherapy Products in Pipeline, 2015
  • Bionor Pharma ASA - Combination Treatment Modalities in Pipeline, 2015
  • Bionor Pharma ASA - Phase II, 2015
  • Bionor Pharma ASA - Phase I, 2015
  • Bionor Pharma ASA - Preclinical, 2015
  • Bionor Pharma ASA - Discovery, 2015
  • Bionor Pharma ASA - Pipeline by Route of Administration, 2015
  • Bionor Pharma ASA - Pipeline by Molecule Type, 2015
  • Bionor Pharma ASA - Recent Pipeline Updates, 2015
  • Bionor Pharma ASA, Other Locations
  • Bionor Pharma ASA, Subsidiaries

List of Figures

  • Bionor Pharma ASA - Pipeline by Top 10 Indication, 2015
  • Bionor Pharma ASA - Pipeline by Stage of Development, 2015
  • Bionor Pharma ASA - Monotherapy Products in Pipeline, 2015
  • Bionor Pharma ASA - Pipeline by Top 10 Route of Administration, 2015
  • Bionor Pharma ASA - Pipeline by Top 10 Molecule Type, 2015
Back to Top